Bronchodilator Responsiveness Measured by Spirometry and Impulse Oscillometry in Patients with Asthma After Short Acting Antimuscarinic and/or Beta-2-Agonists Inhalation
Nicole van der Burg,Carl Ekelund,Leif Bjermer,David Aronsson,Jaro Ankerst,Ellen Tufvesson
DOI: https://doi.org/10.2147/jaa.s442217
2024-01-20
Journal of Asthma and Allergy
Abstract:Nicole MD van der Burg, Carl Ekelund, Leif H Bjermer, David Aronsson, Jaro Ankerst, Ellen Tufvesson Department of Clinical Sciences Lund, Respiratory Medicine, Allergology and Palliative Medicine, Lund University, Lund, Sweden Correspondence: Ellen Tufvesson, Department of Clinical Sciences Lund, Respiratory Medicine, Allergology and Palliative Medicine, Lund University, BMC, D12, Lund, 221 84, Sweden, Email Background: Bronchodilator responsiveness (BDR) in asthma involves both the central and peripheral airways but is primarily relieved with beta-2-agonists and evaluated by spirometry. To date, antimuscarinics can be added as a reliever medication in more severe asthma. We hypothesize that combining both short-acting beta-2 agonist (SABA) and short-acting muscarinic antagonist (SAMA) could also improve the responsiveness in mild-moderate asthma. Therefore, we aimed to compare the direct effects of inhaling SABA alone, SAMA alone or combining both SABA and SAMA on the central and peripheral airways in asthma. Methods: Twenty-three patients with mild-moderate BDR in asthma performed dynamic spirometry and impulse oscillometry before (baseline) and multiple timepoints within an hour after inhalation of SABA (salbutamol), SAMA (ipratropium bromide), or both SABA and SAMA at three different visits. Results: The use of SAMA alone did not show any improvement compared to the use of SABA alone. Inhalation of SABA+SAMA, however, averaged either similar or better BDR than SABA alone in FEV 1 , MMEF, FVC, R5, R20 and R5-R20. Inhaling SABA+SAMA reached a stable BDR in more patients within 0– 10 minutes and also reached the FEV 1 (Δ%)> 12% faster (3.5 minutes) than inhaling SABA alone (5.1 minutes). Inhaling SABA+SAMA was significantly better than SAMA alone in FEV 1 ( p = 0.015), MMEF ( p = 0.0059) and R20 ( p = 0.0049). Using these three variables highlighted a subgroup (30%, including more males) of patients that were more responsive to inhaling SABA+SAMA than SABA alone. Conclusion: Overall, combining SAMA with SABA was faster and more consistent at increasing the lung function than SABA alone or SAMA alone, and the additive effect was best captured by incorporating peripheral-related variables. Therefore, SAMA should be considered as an add-on reliever for mild-moderate patients with BDR in asthma. Keywords: BDR, mild-moderate asthma, central airway, peripheral airways, SABA, SAMA Bronchodilator responsiveness (BDR) in asthma (previously often called "reversibility") generally refers to rapid improvements in forced expiratory volume in 1 second (FEV 1 ) measured within minutes after inhalation of a short-acting bronchodilator. 1,2 Depending on the cohort, 17–57% of asthma patients demonstrate BDR when tested using short-acting beta-2-agonist (SABA). 3,4 Regular use of SABA leads to increased beta-2-receptor tolerance, reduced response to the medication, and increased allergen response and inflammation, therefore, it is no longer recommended as a single reliever medication. 5 Instead, the Global Initiative for Asthma (GINA)-guidelines (2022) recommend mild asthma symptoms are relieved, when necessary, with low-dose inhaled corticosteroids (ICS) and formoterol (a long-acting beta-2-agonists, LABA, with relative rapid onset of action), moderate asthma should also take this combination daily (ie maintenance and reliever), while LAMA is only considered in more severe asthma (ie step 4). 1 In general, most patients with BDR in asthma control their symptoms with ICS+LABA (ie mild-moderate severity); however, since BDR is an indication that the airway smooth muscle is targetable, maybe antimuscarines should be considered before step 4. The short- and long-acting muscarinic antagonists (SAMA and LAMA, respectively) are another types of bronchodilators, instead directly targeting the airway smooth muscle (contributing to the bronchoconstriction), that are suggested to be a useful add-on but are rarely prescribed in asthma. 6 Antimuscarinic bronchodilators are cost-effective medications that tend to be reserved for more severe forms of asthma. 7,8 They have similar properties to the beta-2-agonists in their outcome of bronchodilation, but instead, act by blocking the acetylcholine receptors in smooth muscle cells, thus reducing the airflow limitation. 9 The side effects of antimuscarinics are minor (for example, dry throat related to the anticholinergic effect), and daily use does not induce tolerance. 6,10 Antimuscarinics delivered by ultrafine aerosolization techniques have the potential to target the receptors of the small airways. 11 Using them as add-on therapy has already shown a -Abstract Truncated-
immunology,allergy,respiratory system